A statistical model to predict the reduction of lichenification in atopic dermatitis by Glazenburg, E.J. (Eltjo) et al.
Acta Derm Venereol 95
INVESTIGATIVE REPORT
Acta Derm Venereol 2015; 95: 294–297
© 2015 The Authors. doi: 10.2340/00015555-1881
Journal Compilation © 2015 Acta Dermato-Venereologica. ISSN 0001-5555
Acute symptoms of atopic dermatitis (AD), such as ery­
thema, oedema/papulations and excoriations, respond 
quickly to topical corticosteroid treatment. Conversely, 
lichenification is regarded as a troublesome non-acute 
symptom of chronic AD which can take months of treat­
ment before any improvement is seen. However, very 
little data actually support this opinion. Here, we ana­
lyse lichenification scores in 3 multicentre, short-term 
studies of nearly similar design. Two of these studies 
were active comparator dosage trials administered with 
either fluticasone propionate cream or ointment once 
or twice daily, the third study was a placebo control. In 
each of these 4-weeks studies lichenification was measu­
red weekly. For the evaluation of the lichenification score 
over time a random-coefficients regression model was 
used. In all active treatments lichenification significant­
ly improved (p < 0.005) within one week. Improvement 
continued afterwards, with > 80% of patients scoring no, 
very mild or mild lichenification after 4 weeks. We de­
veloped a model in which the lichenification score drops 
off linearly with the square root of time. The resulting 
convexly-shaped downward time trend of lichenification 
was significant during all treatments. This effect was 
significantly stronger during active treatment than with 
placebo. Fluticasone propionate can improve moderate 
to severe lichenification in a relative short period of time. 
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The efficacy of drugs in the treatment of atopic derma-
titis (AD) is most often described in terms of reduc-
tion of intensity markers like erythema, oedema and 
excoriations, which constitute the Three Item Severity 
(TIS) score (1–4). The same markers are also part of 
scoring systems such as the SCORAD index or Objec-
tive SCORAD, EASI and others (1–3). Hence, there is 
a remarkably good  correlation between TIS and the 
Objective SCORAD (5).
One of the other parameters of the overall scoring 
systems is lichenification, which is defined as thick, 
leathery skin, usually the result of constant scratching 
and rubbing. With prolonged rubbing or scratching, the 
epidermis becomes hypertrophied and this results in 
thickening of the skin and exaggeration of the normal 
skin markings, giving the skin a leathery bark-like ap-
pearance. Lichenification is a common consequence of 
AD and other pruritic (itchy) disorders. It may also arise 
on seemingly normal skin. This type of skin lesion is al-
most invariably present in long-lasting, chronic AD and 
it is not associated with acute AD. Most dermatologists 
consider a certain severity of lichenification as part of 
SCORAD and EASI, even when the acute exacerbation 
of AD is under control and erythema, oedema and/or 
excoriations have a score of 0. A lichenification score 
of 0, meaning that the lichenification has disappeared 
completely, is virtually unattainable in patients with 
chronic AD. Especially severe lichenification is seen 
as a more or less constant feature of AD and some 
trials/reports even state that no, or hardly any, sign of 
improvement was seen in case of lichenification (6, 7).
During the last years many studies were published in 
which the effects of the potent corticosteroid fluticasone 
propionate (FP) in patients with AD were investigated 
(8–10). A recent review summarises the activity, ef-
ficacy and safety profile of topical FP focussing on 
the treatment and prophylaxis of AD (11). In the vast 
majority of these studies acute effects were measured by 
looking at erythema, oedema and excoriations but little 
attention was paid to lichenification. Yet, lichenification, 
being part of the SCORAD index, was scored in many 
of these studies. These studies showed a remarkable 
reduction of mild lichenification within a few weeks. 
In addition, moderate to severe lichenification seemed 
to diminish, albeit not as fast as in the case of mild 
lichenification (reviewed in 11). 
The decrease in lichenification severity appeared to 
develop according to a certain proces. Thus, the aim 
of this study was to collect lichenification data to es-
tablish a potential descriptive model for the reduction 
of lichenification. 
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MATERIALS AND METHODS
All 3 analysed studies were multicentre, randomised, double-
blind studies.  All of the patients included in the studies were 
suffering from moderate to severe eczema at entry (objective 
SCORAD > 15) and are representative of those who will be 
treated according to the SmPC. The study populations were 
well balanced in terms of age, sex and disease severity. 
The characterisation of the analysed studies were as follows: 
(i) FLT001 was a 4-week multicentre double-blind study to 
compare safety and efficacy between once daily (OD) and twice 
daily (BD) administration of FP 0.05% cream in the treatment 
of AD. Patients should suffer from active AD of at least mode-
rate severity and lichenification was scored every week. Study 
FLT001 had 2 arms: a 1:1 randomisation to either FP cream 
OD or FP cream BD with 137 and 133 patients, respectively. 
Patients in this study were aged between 4 months and 62 years. 
(ii) FLT002 was a 4-week multicentre double-blind study to 
compare safety and efficacy with an OD and BD administra-
tion of FP 0.005% ointment in the treatment of AD. Patients 
should suffer from active AD of at least moderate severity and 
lichenification was scored every week. Study FLT002 also 
had 2 arms: a 1:1 randomisation to either FP ointment OD or 
FP ointment BD with 118 and 122 patients, respectively. Pa-
tients in this study were aged between 8 months and 63 years. 
(iii) FLT401 was a 4-week multicentre double-blind study to 
compare safety and efficacy between either OD or BD admi-
nistration of FP 0.005% ointment, or placebo ointment in the 
treatment of AD. Patients should suffer from active AD of at 
least moderate severity and lichenification was scored every 
week. Study FLT401 had 3 arms: a 1:1:1 randomisation to 
either FP ointment OD, FP ointment BD, or placebo ointment, 
with 79, 79, and 76 patients, respectively. Patients in this study 
were aged between 13 and 87 years.
These studies were comparable in so far that in each of these 
studies all SCORAD parameters were scored in an identical 
way. These parameters pertain to the objective parameters 
erythema, oedema/papulations, excoriations, oozing/crusts, 
lichenification and dry skin and the subjective parameters 
itch and sleeplessness. Lichenification, one of the chronic 
parameters of AD, was therefore one of the outcome variables. 
All parameters including lichenification were scored weekly 
according to the following criteria (0: absent, 0.5: very mild, 
1.0: mild, 1.5: mild to moderate, 2.0: moderate, 2.5: severe, 
3.0: very severe). 
Statistical analysis
In these 3 studies lichenification was an ordinal 7-points 
scaled variable ranging from 0 (lichenification absent) to 3 
(very severe lichenification) in steps of 0.5. Firstly, each of 
these studies was analysed separately, followed by a pooled 
analysis of the 3 studies. Linear mixed modelling was used 
to analyse the lichenification score as the dependent variable. 
The following independent variables were entered in the mo-
del: the square root of time (weeks 0–4) and its interaction 
with the treatment group (3 treatments: OD, BD and placebo). 
In a pooled analysis of the 3 studies, study was also entered 
in the model as explanatory factor (3 levels). Because of the 
randomisation at week 0, treatment was not entered as main 
factor in the model as there can be no effect of treatment at 
week 0. In the analysis each subject was supposed to have his/
her own regression curve of lichenification with time. This 
was effectuated by assuming that the intercept and slope of the 
regression model had a bivariate normal distribution across the 
subjects, representing the between-subjects variability of the 
regression curves (“random coefficients”). The residual term, 
representing the within-subject random deviations from the 
subject’s regression curve, was assumed to have a normal dist-
ribution and to be serially correlated between successive weeks 
according to a first order autoregressive structure that was the 
same across the subjects. The following model estimates (with 
standard errors) were obtained from the analyses: the mean of 
the intercepts and slopes across subjects, mean differences in 
slope of OD treatment with BD and placebo treatment. For 
the between-subject variability of the regression curves we 
presented the estimated standard deviations and correlation of 
the intercept and slope. For the within-subject variability we 
presented the estimated standard deviation (SD) and first-order 
autocorrelation coefficient of the residuals. Data was analysed 
using SAS version 9.2.
RESULTS
In total, 749 patients were randomised and analysed, 
distributed over 3 studies. Only 16 (2.2%) of these 
patients, suffering from active, moderate to (very) 
severe AD, showed no signs of lichenification at the 
start of acute treatment of their disease (lichenification 
score = 0), as is shown in Table SI1. The vast majority 
of patients, viz. 537 (72.2%), had a score of ≥ 2 at study 
start, indicating moderate to very severe lichenifica-
tion. Table SII1 shows the distribution characteristics 
of lichenification by study, by treatment and by week.
In all FP treatment arms lichenification significantly 
improved (p < 0.005) within one week. Depending on 
the study, improvement continued afterwards in > 60% 
to > 80% of patients, resulting in a lichenification score 
of ≤ 1 after 4 weeks (see Figs S1–31). Compared to ac-
tive treatment, placebo treatment showed a far lesser 
decrease in the lichenification scores (see Fig. S31)). 
At the start of each of these 3 studies almost all 
subjects had a lichenification score exceeding zero. In 
all treatment groups there was a similar pattern that 
the mean lichenification score dropped off convexly in 
time. After careful model selection it appeared that in 
all 3 studies the best choice was a model that specifies 
a decrement in time that is linear to the square root of 
week number. This model also appeared to result in 
very robust estimates of the slopes across the 3 studies.
In the model a random intercept and a random slope 
between subjects were specified. The model allowed no 
difference in the distribution of intercepts between the 
treatment groups (due to the randomisation), but it did 
allow a difference in mean slope between the treatment 
groups. This mean difference in slopes is the effect of 
interest and it was specified as a fixed effect. The within-
subject residuals were assumed to serially correlate with 
the same variance and first-order autocorrelation across 
patients and weeks. A  separate analysis was first done 
for each of the 3 studies, when after the pooled data of 
the 3 studies were analysed with study as explanatory 
factor, the BD treatment was taken as reference in each 
1http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-1881
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analysis. Table I presents the estimated parameters of 
the mean regression lines (mean intercepts and slopes 
across subjects). Table SIII1 presents the elements of 
the random disturbances around the mean regression 
lines. These disturbances have a between-subjects 
component and a within-subjects component, as men-
tioned earlier. The between-subjects component is a 
result of the variability of the subject’s intercepts and 
slopes across the subjects, represented by the SDs of 
slopes and of intercepts and by the correlation between 
intercepts and slopes in Table SIII1. The within-subjects 
component is formed by the within-subject serially cor-
related residuals around the subject’s own regression 
line, represented in Table SIII1 by the SD of the residuals 
and by the 1st order autocorrelation coefficient between 
successive residuals. 
The variation of mean intercepts between the studies 
denote the between-study differences in mean levels. A 
striking result is that the mean linear decrement of the 
latent lichenification response with the square root of 
time (the slope) during FP treatment is about the same 
between studies and between OD  and BD treatments: 
–0.66 during OD treatment and –0.68 during BD 
treatment. Of course, this decrement is not only due 
to treatment with FP alone. There may be other time 
effects, such as a placebo effect and the regression-to-
the mean artefact due to the selection of patients with 
a high score entering the studies. In order to correct for 
all these other time effects, one may consider the results 
of study FLT401 where also a placebo arm is involved. 
The mean decrement in time is in the placebo group 
much less marked than in the actively treated group: 
the slope is 0.386 (SE = 0.054, hence highly significant) 
points nearer to zero than the slope of –0.673 in the 
BD-treated group. 
In summary, the model in which mean lichenifica-
tion at a certain time-point can be predicted from the 
mean lichenification at the start of treatment can be 
described as:
LCT = LS – slope√week1.
DISCUSSION
By careful statistical interpretation of the data of 3 
comparable studies we developed a formula to predict 
mean lichenification score in AD at a certain time-point. 
This predicted mean score is dependent on 3 parame-
ters, namely the mean lichenification at the start of 
the treatment, the treatment itself (expressed as mean 
decrement of the latent lichenification response with 
the square root of time, giving a slope between –1 and 
0) and the duration of treatment (in weeks). For FP this 
mean decrement of the latent lichenification response 
with the square root of time was strikingly comparable 
over the analysed studies and varied between –0.68 and 
–0.66, based on 4 measurements in time. 
As estimated from the model the mean decrement in 
lichenfication score after 4 weeks of twice daily treat-
ments was 1.34 points which was 0.78 points more than 
the mean decrement during placebo treatment. Only a 
small mean difference of 0.05 points after 4 weeks was 
estimated between once- and twice-daily treatment. 
However, an individual patient may behave in time very 
differently from the mean. Each patient may follow 
his or her own time path of lichenification score with 
serially correlated random fluctuations around that path. 
As a consequence the decompostion of total variance 
in a between-subjects and a within-subject component 
as well as the total variance itself of lichenification score 
may vary in time in a complicated way. Therefore, 5 
parameters in the model were specified to take into ac-
count the (co)variance structure of lichenification score 
(see Table SIII1).
The total number of 749 patients entering the stu-
dies dropped off to 532 at week 4. In the linear mixed 
model analysis all 749 patients had been involved, 
with missing values appropriately imputed through 
the restricted maximum likelihood estimation method.
The model cannot only be used to predict disappea-
rance of lichenification, it also can be used to predict 
how lichenification will develop after a certain period 
of treat ment. Again taking FP with a slope of 0.67 as 
example, it can be predicted that after 4 weeks of treat-
ment a very severe lichenification (score 3) will have 
been diminished to 3–0.67 × √4 = 1.66. A score of this 
magnitude is classified as mild to moderate lichenifica-
Table I. Results of the analysis of the random-effects regression models of the lichenification score
Study Intercept (SE) Slope BD (SE) Slope OD – BD (SE) Slope Plac – BD (SE)
FLT001 1.919 (0.038) –0.666 (0.034) 0.034 (0.044) NA
FLT002 2.226 (0.032) –0.666 (0.036) 0.019 (0.050) NA
FLT401 1.657 (0.055) –0.673 (0.042) 0.019 (0.052) 0.386 (0.054)
3 studies FLT001: 1.926 (0.037)
FLT002: 2.225 (0.039)
FLT401: 1.652 (0.040)
–0.668 (0.021) 0.025 (0.028) 0.382 (0.048)
Intercept: the estimated mean intercept across subjects; Slope BD: the estimated mean slope across subjects with the square root of week in the twice daily 
(BD) group; Slope OD-BD: the estimated difference between the mean slopes in the once daily (OD) and BD treatment groups; Slope Plac-BD: the estimated 
difference between the mean slopes in the placebo and BD treatment groups.
1LCT = mean Lichenification at Certain Time-point; LS = mean Lichenification 
at Start; slope = number, dependent of treatment.
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tion. This calculation shows a good correlation from 
what is seen (Fig. S1–S31).
The value of the slope is the most important factor in 
the lichenification diminishing process. The potency of 
the steroid is probably some kind of prediction instru-
ment for the value of the slope. 
Until a few years ago when long-term treatment 
of chronic AD patients consisted of an advice to use 
emollients and bath oil, hardly any patient was treated 
with a corticosteroid for more than 4 weeks. Although 
the use of emollients and bath oil will result in less 
exacerbations than doing nothing at all (and this is in 
fact the real placebo treatment), it is unlikely that under 
such circumstances no exacerbation will happen in a 
time period of more than 2 years. Our model is based 
upon the assumption that no exacerbations of AD will 
occur during the reduction period, a chronic AD patient 
will undoubtedly suffer from an exacerbation in such a 
long time-period. An optimal treatment with emollients 
and bath oils will diminish the number of exacerbations 
compared to doing nothing at all, but results from long-
term studies have shown that a treatment with only 
emollients and bath oil is inferior to the same treatment 
where FP is added twice weekly (8–10, 12).
A few studies with a long-term treatment during such 
a time period were performed with FP (8–10, 12). In 
these studies treatment consisted of an acute treatment 
period of daily application of FP during 4 weeks (as in 
the studies used for the development of the prediction 
model described in this manuscript) followed by a 
maintenance phase of 16 weeks where FP was applied 
twice weekly to the areas that were usually affected. The 
majority of patients on active maintenance treatment 
indeed reached the 20 weeks total treatment endpoint 
without an exacerbation and most of these had a liche-
nification score of 0, indicating that no exacerbations 
during a certain time-period will for the greater part of 
patients lead to a non-lichenified skin. Applying our 
model on these long-term studies showed a good cor-
relation between our predictive model and the actual 
results of these long-term studies. However, it should 
be remembered that our predictive model is based upon 
daily treatment with FP while in these long-term studies 
patients were treated twice weekly during 16 out of 20 
weeks. Theoretically it would be very interesting to 
conduct a study where daily application for 20 weeks 
is compared with OD application for 4 weeks in com-
bination with twice weekly application for 16 weeks 
to find out if differences consist regarding the values 
of the slope between these 2 treatments.
Currently we only have slope values of FP and pla-
cebo. It would be very interesting to find out how other 
molecules compare to values of 0.67 viz. 0.29 and what 
the consequences might be for the long-term treatment 
of lichenification using these molecules. Based upon our 
predictive model and based upon the long-term results 
of other studies, FP is a suitable candidate to use as 
treatment of acute as well as chronic parameters of AD. 
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